Triochem Products Limited has filed its quarterly statement of defaults with BSE Limited, reporting a clean debt profile for the quarter ended December 31, 2025. The Mumbai-based pharmaceutical company submitted the mandatory disclosure under SEBI Listing Obligations and Disclosure Requirements Regulations 2015 on January 7, 2026.

Debt Position Summary

The company's financial position reflects zero outstanding debt across all categories during the reporting quarter. The comprehensive statement covers loans from banks and financial institutions, unlisted debt securities, and total financial indebtedness.

Regulatory Compliance

The filing was made in accordance with BSE Circular No. LIST/COMP/50/2019-20 dated January 15, 2020, which mandates listed companies to disclose their debt default status quarterly. Company Secretary and Compliance Officer Ureca Deolekar signed the statement digitally, ensuring proper authentication of the submitted information.

Company Background

Triochem Products Limited operates from its registered office at Sambava Chambers, Fort, Mumbai, with Corporate Identity Number L24249MH1972PLC015544. The company trades on BSE under security code 512101 with ISIN number INE331E01013. The pharmaceutical sector entity maintains its corporate website at www.triochemproducts.com and can be reached at info@amphray.com .

Financial Health Indicator

The zero debt position across all categories indicates the company's conservative financial approach during the quarter ended December 31, 2025. This debt-free status eliminates concerns about interest payment defaults or principal repayment issues that could impact shareholder value or regulatory standing.

Triochem Products Limited has successfully completed the postal ballot process for its proposed asset sale worth ₹11.81 crore, with shareholders providing unanimous approval on December 12, 2025. The chemical and pharmaceutical manufacturer had earlier reported operational challenges and proposed the asset sale as a strategic initiative to optimize its asset base.

Official Postal Ballot Completion

The company has formally concluded the postal ballot process with complete regulatory compliance. The scrutinizer's report, submitted by Ms. Ragini Chokshi, Company Secretary, confirmed the successful completion of the voting process:

The voting process excluded 2,04,190 shares held by related parties, ensuring full compliance with regulatory requirements under Section 188 of the Companies Act, 2013, and SEBI regulations for related party transactions.

Asset Sale Transaction Details

The approved transaction involves the disposal of immovable property situated in Maharashtra to a related party. The asset valuation presents significant value realization potential:

The substantial premium over the written down value demonstrates the strategic value of this asset disposal for the company's financial restructuring efforts.

Recent Financial Performance Context

The asset sale approval comes amid the company's ongoing operational challenges reflected in its Q2 FY2026 results:

Despite revenue growth, the widening losses underscore the importance of the asset sale proceeds for the company's financial stability and future strategic initiatives.

Regulatory Compliance and Next Steps

The transaction constitutes a Material Related Party Transaction under applicable regulations, which necessitated the postal ballot approval process. With all regulatory requirements now fulfilled, the company can proceed with the asset sale completion, expected by January 31, 2026.

The management has indicated that the sale proceeds will be utilized for new business ventures and strategic initiatives in the chemicals and pharmaceuticals sector. The unanimous shareholder support reflects confidence in the management's strategic direction and the potential for value creation through this asset optimization initiative.